Skip to main content
OpenTrials
Completed

NCT Number: NCT03003494

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ospedale Generale Regionale "Miulli", Acquaviva Delle Fonti (BA), Italy

Loading trial locations.

About this study

Purpose:

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent prior to participation
  • Female and male patients = 40 years of age
  • Patients diagnosed with COPD and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and therapeutic plan recommendation

Exclusion criteria

  • Patients with contraindications according to Spiolto® Respimat® Summary of Product Characteristics (SmPC)
  • Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months
  • Patients continuing LABA-Inhalative Corticosteroids (ICS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists
  • Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks
  • Pregnancy and lactation
  • Patients currently listed for lung transplantation
  • Current participation in any clinical trial or any other non-interventional study of a drug or device

Treatment and study plan

Spiolto® Respimat®

Drug

observations taken in a period of approximately 6 weeks

Other names: INSPIOLTO, SPIOLTO, STIOLTO, VAHELVA, YANIMO

Primary outcomes

  1. Percentage of Patients With Therapeutic Success at Week 6 Approximately (Approx.) (Visit 2)

    Time frame: after approximately 6 weeks

    Therapeutic success defined as at least 10-point increase of Physical functioning questionnaire (PF-10 ) score after approximately 6 weeks of Spiolto® Respimat® treatment The PF-10 used for assessing the primary outcome "physical functioning" is a sub-domain of the validated Short Form 36 (SF-36 ) and consists of 10 questions evaluating the extent of experienced restrictions while conducting usual activities. Each question of the PF-10 can be answered with "yes, limited a lot", "yes, limited a little" or "no, not limited at all", with a score of 1, 2 or 3. The sum of the scores of the 10 questions results in a value between 10 (a patient answering all questions with "yes, limited a lot") and 30 (a patient answering all questions with "no, not limited at all"). The final sum of the individual scores was standardized to a range of 0 to 100 using the following formula: [(sum of scale items - 10) * 100] / 20. Higher scores indicate better physical functioning.

Secondary outcomes

  1. The Median Change in the PF-10 Score From Visit 1 (Baseline) to Visit 2

    Time frame: Baseline (visit 1) and after approx. week 6 (visit 2)

    The change in PF-10 score was determined by taking into account the individual change of each patient between Baseline (Visit 1) and Week 6 (approx.) (Visit 2) and then the median for change from baseline values across all subjects was calculated.

  2. Patients General Condition Evaluated by the Physician (PGE Score) at Visit 1 and Visit 2

    Time frame: Baseline (visit 1) and after approx.week 6 (visit 2)

    The patient's general condition was evaluated by means of Physician's Global Evaluation (PGE) score. The PGE score is documented on a scale from 1 (poor) to 8 (excellent) at both visits. 1-2: poor; 3-4: satisfactory; 5-6: good; 7-8: excellent

  3. Patient Overall Satisfaction With Spiolto® Respimat®

    Time frame: After approx. 6 weeks of treatment initiation

    Patients were asked how overall satisfied they were with the Spiolto® Respimat® treatment at Week 6 (approx.) (Visit 2).

  4. Patient Satisfaction With Inhaling From the Respimat® Device

    Time frame: After approx. 6 weeks of treatment initiation

    Patients were asked how satisfied they were by inhaling with the Respimat® device at Week 6 (approx.) (Visit 2)

  5. Patient Satisfaction With Handling of the Respimat® Inhalation Device

    Time frame: After approx. 6 weeks of treatment initiation

    Patients were asked how satisfied they were with handling of the Respimat® inhalation device at Week 6 (approx.) (Visit 2).

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Acronym: OTIVACTO

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Dec 28, 2016
Registry last updated
Sep 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.